$DCOY News

Decoy Therapeutics Q1 EPS $(4.18) Misses $(4.08) Estimate

Decoy Therapeutics Inc. (DCOY) Discusses Corporate Overview and Pipeline Progress in Antiviral Drug Development Transcript

Decoy Therapeutics Regains Nasdaq Compliance

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Decoy Therapeutics shares are trading lower after the company announced a 1-for-12 reverse stock split.

Decoy Therapeutics Announces 1‑For‑12 Reverse Stock Split Effective March 6

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

Ladenburg Thalmann Initiates Coverage On Decoy Therapeutics with Buy Rating, Announces Price Target of $2.5

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

Decoy Therapeutics shares are trading higher after the company announced it reached global access commitment agreement to focus on the development of a global manufacturing platform for peptide-conjugate antivirals under the Gates Foundation Access agreement.

Decoy Therapeutics Announces Funded Development Of Global Manufacturing Platform For Peptide‑Conjugate Antivirals Under Gates Foundation Access Agreement

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Salarius: Q2 Earnings Snapshot

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard

Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies